1Michaels SH, Clark R, Kissinger P. Declining morbidity and monality patients with advanced humall immunodeficiency vires infection[J]. N Engl J Med,1998,339:405-406.
2曹韵贞.艾滋病临床诊断、治疗及护理[M].北京:人民卫生出版社,2001.148-150.
3Cao Y,Hb DD,Todd J.et al. Clinicl evaluation If Branched DNA signal amplification for quantifying HIV type human plasma[J]. AIDS Hum Retroviruses, 1995,11 : 353-361.
1Blower S et al. Predicting the unpredictable: the transmission of drug resistant HIV. In: Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America; October 25-28, 2001; San Francisco. Abstract 655
2Richman D et al. The analysis of drug resistance from the HIV Cost and Service Utilization Study (HCSUS). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2001; Chicago. Abstract LB-17
3Barrie KA et al. Virology, 1996; 219(2): 407 - 416
4Lech WJ et al. J Virol, 1996; 70:2038 - 2043
5Persaud D et al. Arresting HIV-1 evolution with highly active antiretroviral therapy (HAART). In: Program and abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America; October 25-28,2001; San Francisco. Abstract 778
6Weiser B et al. HIV-1 in plasma and genital tract of women: dual infection and drug resistance in different compartments. In: Program and abstracts of the 39th Annual Meetng of the Infectious Diseases Society of America; October 25-28, 2001; San Francisco. Abstract 782
7Matthias E et al. Prognosis of HIV-1 infected drug-naive patients starting potent antiretroviral therapy: multi-cohort analysis of 12040 patients. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2001; Chicago.Abstract LB-18
8, Developed by the panel on Clinical Practices for Treatment of HIV Infection Convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation; February 4,2002
9Christine K et al. A randomized comparative study of switch to trixivir compared to HAART in patients successfully treated with HAART. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2001; Chicago.Abstract I-671
10Gruzdev B et al. TMC125 is a highly potent non-nucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral therapy (ART)-naive, HIV1 infected subjects. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICA AC); December 16-19, 2001; Chicago. Abstract I-668
